MMP2 and neoplasm: The Kaplan–Meier analysis showed that the RFS was 90 or 80% in patients with an MMP-2-negative, oestrogen receptor-negative or progesterone receptor-negative primary tumour, respectively, while it was 56% in the MMP-2-positive tumours in both oestrogen- or progesterone receptor groups (P=0.047, 0.023).